X
X
Total 393357 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bipolar neuron of Bolwig nerve | ILX:0101315 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Bipolar Progenitor Cell | A type of NG2 positive cell that resemble oligodendrocyte precursors | ILX:0101316 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Birmingham object recognition battery | a set of standardized procedures for assessing neuropsychological disorders of visual object recognition which includes tests to assess low-level aspects of visual perception (using same-different matching of basic perceptual features, such as orientation, length, position and object size), intermediate visual processes (e.g., matching objects different in viewpoint), access to stored perceptual knowledge about objects (object decision), access to semantic knowledge (function and associative matches) and access to names from object (picture naming). | ILX:0101317 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| BIRN-INCF Derived Data Project | The Derived Data Working Group is focused on understanding, addressing and solving the known difficulties of sharing and combining data across multiple sites after post-processing and/or data analysis. This WG is working closely with researchers at UC Irvine, Columbia, Duke, MIT, MRN and INCF on these goals:-Develop provenance and derived data extraction scripts for common neuroimaging analysis software and pipelines-Extend tools and specifications for international community requirements-Create/curate an initial neuroimaging terminology and ontology for derived data and common neuroimaging concepts-Augment/improve derived data import and query functionality for multi-site derived data federationsNeuroimaging data often involves many aspects of image and signal processing on the raw data which takes considerable time and expertise. Making such derived data available in a structured and well documented way is of interest to the international neuroimaging community. The availability of large multi-site datasets such as the Function BIRN schizophrenia datasets and the 1000 Functional Connectomes Project data provides researchers with well-documented and structured raw data. The addition of a similarly well-documented and structured form for derived data is the focus of this working group. Although the Function BIRN had made strides in developing the XCEDE XML schema for the structured storage and interchange of neuroimaging derived data, being able to extract both the derived results and the provenance of what happened to the data during the analytical manipulations directly from the software and pipelines performing the computations is missing. Without this piece, documenting derived data provenance and results becomes a burden on the researchers who are more interested in addressing scientific hypotheses than in documenting who the result was obtained for other users.To address the needs for providing derived data to the public community we have formed the derived data working group. This group brings together researchers with extensive experience with neuroimaging studies and specifically with large-scale data analysis and management using the more prevalent software packages in the field, e.g. SPM and FSL. This working group leverages the experience of the group both within BIRN and in communication with other researchers through the INCF to identify information needed for a provenance description to be useful. Face-to-face meetings to discuss needs and possible approaches were held in 2011 and 2012 at UC Irvine in January, at OHBM in June 2011, at the INCF Standards for Data Sharing task force meeting in September, and a fourth meeting in November at the annual meeting for the Society for Neuroscience.Once these details are established and there is consensus among the community, we will address the format for which this information will be stored. Initially we are focusing on XML schemas that integrate with the existing XCEDE XML schema (W3C Prov model) which describes neuroimaging data sets in general. After identifying the needed pieces of information and their storage format we will both work with the developers of the software packages to integrate the provenance schemas into their distributions or where not possible, write scripts to extract the information. All products of the derived data group are open-source and freely available to the community through the BIRN public wiki and INCF GitHub repositories. | ILX:0101318 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Bisoprolol | A cardioselective beta-1-adrenergic blocker. It is effective in the management of hypertension and angina pectoris. (PubChem) Pharmacology: Bisoprolol is a competitive, beta(1)-selective (cardioselective) adrenergic antagonist. Bisoprolol is used to treat hypertension, arrhythmias, coronary heart disease, glaucoma, and is also used to reduce non-fatal cardiac events in patients with heart failure. Activation of beta(1)-receptors (located mainly in the heart) by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Drugs such as Bisoprolol that block these receptors therefore have the reverse effect: they lower the heart rate and blood pressure and hence are used in conditions when the heart itself is deprived of oxygen. They are routinely prescribed in patients with ischemic heart disease. In addition, beta(1)-selective blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. Bisoprolol is lipophilic and exhibits no intrinsic sympathomimetic activity (ISA) or membrane stabilizing activity. Mechanism of action: Bisoprolol selectively blocks catecholamine stimulation of beta(1)-adrenergic receptors in the heart and vascular smooth muscle. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Bisoprolol can also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles, causing bronchospasm. Drug type: Approved. Small Molecule. Drug category: Adrenergic Agents. Adrenergic beta-Antagonists. Antihypertensive Agents. Sympatholytics | ILX:0101319 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Bitolterol | Bitolterol mesylate is a beta-2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and COPD. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001. (Wikipedia) Pharmacology: Bitolterol, an adrenergic bronchodilator, is a prodrug that widens constricted airways in the lungs by relaxing the smooth muscles that surround the bronchial passages. Bitolterol probably does not affect the inflammation in the lung, such as in bronchitis. Bitolterol is unique in that it is a prodrug because it must first be metabolized by the body before it becomes active. Mechanism of action: Bitolterol is an adrenergic beta-2 agonist. Asthma is a breathing involving narrowing of the bronchial tubes. This narrowing is caused by muscle spasm and inflammation within the bronchial tubes. Bitolterol relaxes the smooth muscles surrounding these airway tubes, therefore, increases the diameter and ease of air flow through the tubes. Drug type: Small Molecule. Withdrawn. Drug category: Bronchodilator Agents. Selective beta-2-adrenoreceptor agonists | ILX:0101320 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Bits Allocated | Number of bits allocated for each pixel sample. Each sample shall have the same number of bits allocated. | ILX:0101321 | 6 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Bits Stored | Number of bits stored for each pixel sample. Each sample shall have the same number of bits stored. See PS 3.5 for further explanation. | ILX:0101322 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Bitter taste sensation | ILX:0101323 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Bitufted | Two tufts in opposite directions | ILX:0101324 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Bivalirudin | Synthetic 20 residue peptide (thrombin inhibitor) Pharmacology: Angiomax directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release Mechanism of action: Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Drug type: Approved. Biotech. Investigational. Drug category: Anticoagulants. Antithrombotic Agents | ILX:0101325 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Black | A color that lacks any hues as parts. | ILX:0101326 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blastula cat | An early stage of embryonic development where implantation in the wall of the uterus occurs, 30 to 40 hours. | ILX:0101327 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blastula dog | An early stage of embryonic development where implantation in the wall of the uterus occurs, days 9 to 15. | ILX:0101328 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blastula ferret | An early stage of embryonic development where implantation in the wall of the uterus occurs, days 4.5 to 6. | ILX:0101329 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blastula human | An early stage of embryonic development where implantation in the wall of the uterus occurs, days 4 to 6. | ILX:0101330 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blastula mouse | An early stage of embryonic development where implantation in the wall of the uterus occurs, days 4 to 5. | ILX:0101331 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blastula rat | An early stage of embryonic development where implantation in the wall of the uterus occurs, days 4 to 5. | ILX:0101332 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blastula xenopus | An early stage of embryonic development where the blastomeres become arranged around the outside, with a central fluid filled cavity, the blastocoel (3 to 7 hours) OR the stages from 64-cell embryo to Nieuwkoop and Faber stage 9, during which the solid morula acquires an internal cavity. (Xenopus anatomy and development: http://purl.org/obo/owl/XAO#XAO_1000003) | ILX:0101333 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blattaria | ILX:0101334 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X